Stem cells and modeling Huntington's disease in our final Therapeutics Conference report
Strategies for getting rid of mutant huntingtin & clinical trial updates: day 2 of the HD therapeutics conference
The news has recently been full of stories about CRISPR, a new "jaw-dropping" DNA-editing technology. Hype or hope?
Proteins and DNA - Jeff and Ed report from day 1 of the 2016 #huntingtonsdisease therapeutics conference
Researchers design a virus to more effectively deliver gene-silencing drugs throughout the brain.
Sleep deficits precede motor problems in HD
Phase 2/3 clinical trial results prove inconclusive for Huntington's drug cysteamine.
An existing drug could give a boost to HD brain cells – but it may need more testing before it’s back in the clinic
Companions of HD gene carriers are more likely to notice psychological changes in presymptomatic HD.
Fingolimod, a drug used in multiple sclerosis, prevents memory problems in HD mice. Would it work in patients?
A new book for researchers describes a century of HD anatomy and presents evidence that HD affects the whole brain.